Human papillomavirus vaccine and systemic lupus erythematosus

Clinical Rheumatology

Volumn 32, Issue 9, 2013, Pages 1301-1307

  Gatto, Mariele ^a   Agmon Levin, Nancy ^b,c   Soriano, Alessandra ^d   Manna, Raffaele ^d   Maoz Segal, Ramit ^b   Kivity, Shaye ^b,c   Doria, Andrea ^a   Shoenfeld, Yehuda ^b,c  

^a UNIVERSITY OF PADOVA   (Italy)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d CATHOLIC UNIVERSITY   (Italy)

Author keywords

Anti phospholipids antibodies; ASIA; Autoimmunity; Human papillomavirus; Systemic lupus erythematosus; Vaccine

Indexed keywords

ANTICONVULSIVE AGENT; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BELIMUMAB; C REACTIVE PROTEIN; CALCIUM; COMPLEMENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; LA ANTIBODY; METHYLPREDNISOLONE; PHOSPHOLIPID ANTIBODY; PREDNISONE; RO ANTIBODY; STEROID; VITAMIN D; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANEMIA; ANOREXIA; APHTHOUS STOMATITIS; ARTHRALGIA; ARTHRITIS; ARTICLE; ASTHENIA; BONE MARROW BIOPSY; CERVICAL LYMPHADENOPATHY; CLINICAL ARTICLE; CLINICAL FEATURE; COMMON COLD; DIARRHEA; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; ERYTHROCYTE SEDIMENTATION RATE; FAMILY HISTORY; FATIGUE; FEMALE; FEVER; HAIR LOSS; HEADACHE; HUMAN; HUMAN TISSUE; IMMUNIZATION; INFLAMMATION; LEUKOPENIA; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; LUPUS LIKE SYNDROME; LYMPHADENOPATHY; LYMPHOCYTOPENIA; MALAISE; MALAR RASH; MEDICAL HISTORY; MYALGIA; PERIORBITAL EDEMA; PHARYNGODYNIA; PHARYNX DISEASE; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEIN LOSING GASTROENTEROPATHY; PROTEINURIA; PYREXIA IDIOPATHICA; RASH; REMISSION; RISK FACTOR; SEIZURE; SEROLOGY; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS RASH; THROMBOCYTOPENIA; URTICARIA; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; WEAKNESS; WEIGHT REDUCTION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PAPILLOMAVIRUS VACCINES; RISK FACTORS; TIME FACTORS; VACCINATION; YOUNG ADULT;

EID: 84883250127     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2266-7     Document Type: Article

References (44)

1. Paavonen J (2007) Human papillomavirus infection and the development of cervical cancer and related genital neoplasias. Int J Infect Dis 11(Suppl 2):S3-S9
2. Carter JR, Ding Z, Rose BR (2011) HPV infection and cervical disease: a review. Aust N Z J Obstet Gynaecol 51:103-108
3. Jamal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
4. Balofsky A, Agmon-Levin N, Shoenfeld Y (2010) The new H1N1 and HPV vaccines and old fears. Curr Opin Rheumatol 22:431-436
5. Descamps D, Hardt K, Spiessens B et al (2009) Safety oh human papilloma virus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccine 5:332-340
6. Ault KA (2007) Future II study group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369:1861-1868
7. Garland SM, Hernandez-Avila M, Wheeler CM et al (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928-1943
8. Brown DR, Kjaer SK, Sigurdsson K et al (2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. Infect Dis 199:926-935
9. Harper DM, Franco EL, Wheeler CM et al (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367:1247-1255
10. Slade BA, Leidel L, Vellozzi C et al (2009) Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 302:750-757
11. Franco EL, Harper DM (2005) Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 23:2388-2394
12. Tomljenovic L, Shaw CA (2012) Too fast or not too fast: the FDA's approval of Merck's HPV vaccine Gardasil. J Law Med Ethics 40:673-681
13. Orbach H, Agmon-Levin N, Zandman-goddard G (2010) Vaccines and autoimmune diseases of the adult. Discov Med 9:90-97
14. Verstraeten T, Descamps D, David MP et al (2008) Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 26:6630-6638
15. Soldevilla HF, Briones SF, Navarra SV (2012) Systemic lupus erythematosus following HPV immunization or infection? Lupus 21:158-161
16. Cui H, Xue H, Yang L, Liu D, Qi L, Zhang N (2012) Missense polymorphisms within IL-10R1 exons are not associated with systemic lupus erythematosus in Chinese. Lupus 21:1232-1236
17. Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y (2012) Systemic lupus erythematosus one disease or many? Autoimmun Rev 11:593-595
18. Strickland FM, Hewagama A, Lu Q et al (2012) Environmental exposure, estrogen and two X chromosomes are required for disease development in an epigenetic model of lupus. J Autoimmun 38:J135-J143
19. Gatto M, Zen M, Ghirardello A et al (2013) Emerging and critical issues in the pathogenesis of lupus. Autoimmun Rev 12(4):523-536
20. Bijl M, Agmon-Levin N, Dayer JM, Israeli E, Gatto M, Shoenfeld Y (2012) Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment. Autoimmun Rev 11:572-576
21. Agmon-Levin N, Paz Z, Israeli E et al (2009) Vaccines and autoimmunity. Nat Rev Rheumatol 5:648-652
22. Doria A, Canova M, Tonon M et al (2008) Infections as triggers and complications of systemic lupus erythematosus. Autoimmun Rev 8:24-28
23. Agmon-Levin N, Zafrir Y, Paz Z et al (2009) Ten cases of systemic lupus erythematosus related to hepatitis B vaccine. Lupus 18:1192-1197
24. Stübgen JP (2012) Immune-mediated myelitis following hepatitis B vaccination. Autoimmun Rev 12(2):144-149
25. Nohynek H, Jokinen J, Partinen M et al (2012) AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 7:e33536
26. Saad CG, Borba EF, Aikawa NE et al (2011) Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann Rheum Dis 70(6):1068-1073
27. Shoenfeld Y, Agmon-levin N (2011) 'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 36:4-8
28. Israeli E, Agmon-Levin N, Blank M et al (2009) Adjuvants and autoimmunity. Lupus 18:1217-1225
29. Doria A, Iaccarino L, Ghirardello A et al (2006) Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 119:700-706
30. Lyrio LD, Grassi MF, Santana IU et al (2013) Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus. Rheumatol Int 33(2):335-340
31. Klumb EM, Pinto AC, Jesus GR et al (2010) Are women with lupus at higher risk of HPV infection? Lupus 19:1485-1491
32. Doria A, Briani C (2008) Lupus: improving long-term prognosis. Lupus 17:166-170
33. Doria A, Zen M, Canova M et al (2010) SLE diagnosis and treatment: when early is early. Autoimmun Rev 10:55-60
34. Mok CC, Ho LY, Fong LS, To CH (2012) Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis [Epub ahead of print]
35. Conti F, Rezai S, Valesini G (2008) Vaccination and autoimmune rheumatic diseases. Autoimmun Rev 8:124-128
36. Chang J, Campagnolo D, Vollmer TL, Bomprezzi R (2011) Demyelinating disease and polyvalent human papillomavirus vaccination. J Neurol Neurosurg Psychiatry 82:1296-1298
37. Souayah N, Michas-martin PA, Nasar A et al (2011) Guillain-Barré syndrome after Gardasil vaccination: data from vaccine. Adverse Event Reporting System 2006-2009. Vaccine 29:886-889
38. Sutton I, Lahoria R, Tan I, Clouston P, Barnett M (2009) CNS demyelination and quadrivalent HPV vaccination. Mult Scler 15:116-119
39. Future I/II Study Group, Dillner J, Kjaer SK, Wheeler CM et al (2010) Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 341:c3493
40. Chao C, Klein NP, Velicer CM et al (2012) Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med 271:193-203
41. Tomljenovic L, Shaw CA (2012) No autoimmune safety signal after vaccination with quadrivalent HPV vaccine Gardasil? J Intern Med 271(2):193-203
42. van Assen S, Agmon-Levin N, Elkayam O et al (2011) EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 70:414-422
43. van Assen S, Bijl M (2012) Immunization of patients with autoimmune inflammatory rheumatic diseases (the EULAR recommendations). Lupus 21:162-167
44. Soriano A, Manna R (2012) Quantifying the efficacy of influenza vaccine. Lancet Infect 12:659-660